Navigation Links
The American Society for Microbiology honors George L. Drusano

The winner of the esteemed Cubist-ICAAC Award is George L. Drusano, M.D., Institute for Therapeutic Innovation of the University of Florida, for his application of pharmacokinetic and pharmacodynamic modeling to antiviral and antimicrobial drug development. According to his nominator, Michael Dudley, Rempex Pharmaceuticals, "Drusano and his colleagues have published groundbreaking work using pharmacokinetics/pharmacodynamics to simulate and then validate dosing regimens to maximize the safety and efficacy of antibiotics. The breadth and importance of his work is remarkable."

After graduating magna cum laude, ΦΒΚ from the Honors Program at Boston College, Drusano received his M.D. from the University of Maryland School of Medicine where he graduated cum laude, ΑΩΑ. He completed his medical internship and residency at the University of Maryland Hospital, where he was Chief Resident and also a Fellow in Medicine in Infectious Diseases.

Drusano, a Fellow of the American Academy of Microbiology and the Infectious Diseases Society of America (IDSA), is an active reviewer and has served as editor of the section of pharmacology and experimental therapeutics for Antimicrobial Agents and Chemotherapy for 10 years. Currently he is an Editor for mBio. He has authored over 290 articles.

Also an active volunteer, Drusano was a member of the Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC) Program Committee and the IDSA Program Committee. He has served on multiple National Institute of Allergy and Infectious Diseases (NIAID) Review Groups and as an ad hoc member of NIAID Council on two occasions to support issues regarding emergence of bacterial resistance. He also serves as a consultant to NIAID and CDC on Biodefense issues. Drusano has been a member of the Subcommittee on Guidelines for Bacteremia and Endocarditis of the Antimicrobial Agents Use Committee, a joint effort of the IDSA and the Food and Drug Administration. In 2010, he was Chair of the Gordon Conference on New Antimicrobial Discovery and Development. He has won a number of awards, including being named Distinguished Investigator of the Year (2003) by the American College of Clinical Pharmacology. Most recently, he was named recipient of the Maxwell Finland Award for Scientific Achievement for 2012 from the National Foundation for Infectious Diseases.

An active researcher, Drusano has focused on mathematical modeling and the pharmacodynamics of anti-infective chemotherapy, especially the pharmacodynamics of fluoroquinolone antimicrobials, anti-tuberculosis agents, multiple anti-viral agents and the therapy of biodefense pathogens. Paul G. Ambrose, Institute for Clinical Pharmacodynamics, says, "Drusano is a distinguished scholar and scientist who pioneered work in anti-infective pharmacology and antimicrobial resistance, and helped redefine infectious disease chemotherapy as we know it today."


Contact: Garth Hogan
American Society for Microbiology

Related biology news :

1. The American Society for Microbiology honors Ken Cadwell
2. American Chemical Society global program tackles safe drinking water in Colombia
3. The American Society for Microbiology honors Marc Torrent
4. The American Society for Microbiology honors Joshua Obar
5. AMP joins the Federation of American Societies for Experimental Biology
6. American Chemical Societys highest honor goes to Stephen J. Lippard, Ph.D.
7. Medicine, energy topics of Kavli lectures at American Chemical Society meeting
8. Save the date: American Chemical Society National Meeting, Sept. 8-12, 2013, in Indianapolis
9. Body mass index of low income African-Americans linked to proximity of fast food restaurants
10. OU microbiologists elected as fellows in the American Academy of Microbiology
11. American Chemical Society resource connects scientists, discoveries, chemistry & biology interface
Post Your Comments:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... NEW YORK , October 13, 2015 ... biotechnology acceleration and development company, has entered into a ... New York and Paris, France ... --> --> This collaborative ... a highly respected scientific advisory team as well as ...
(Date:10/13/2015)... TORONTO , Oct. 13, 2015  Generex Biotechnology ... has entered into a non-binding Letter of Intent (LOI) with ... that has developed a proprietary cooling technology designed to improve ... the United States and three million ... of 25 and 44 diagnosed as infertile.  For 42% of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from ... in the U.S. for the ablation of prostate tissue. Sonablate® is the first ...
(Date:10/13/2015)... 13, 2015 the United States ... .  PRCC represents about 14% of all new cases of kidney ... Canada and Europe . ...   --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) ... and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in a global ...
Breaking Biology Technology: